Form 4: Monopar Therapeutics Director Sells Shares
Insider Transaction (Form 4)
Kim R Tsuchimoto, a Director of Monopar Therapeutics, sold 4,090 shares of common stock on August 26, 2026.
Summary
- Open-market sale: disposed of 485 Common Stock at $108.83 ($52,783) on August 26, 2026; holds 11,001 after (Direct).
- Open-market sale: disposed of 615 Common Stock at $109.56 ($67,379) on August 26, 2026; holds 10,386 after (Direct).
- Open-market sale: disposed of 700 Common Stock at $110.65 ($77,455) on August 26, 2026; holds 9,686 after (Direct).
- Open-market sale: disposed of 1,098 Common Stock at $111.84 ($122,800) on August 26, 2026; holds 8,588 after (Direct).
- Open-market sale: disposed of 602 Common Stock at $112.93 ($67,984) on August 26, 2026; holds 7,986 after (Direct).
- Open-market sale: disposed of 590 Common Stock at $113.84 ($67,166) on August 26, 2026; holds 7,396 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $455,567 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Kim R Tsuchimoto — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-26 | Open-market sale | Common Stock | 485 | $109 | $52.8K | 11,001 |
| 2026-08-26 | Open-market sale | Common Stock | 615 | $110 | $67.4K | 10,386 |
| 2026-08-26 | Open-market sale | Common Stock | 700 | $111 | $77.5K | 9,686 |
| 2026-08-26 | Open-market sale | Common Stock | 1,098 | $112 | $122.8K | 8,588 |
| 2026-08-26 | Open-market sale | Common Stock | 602 | $113 | $68.0K | 7,986 |
| 2026-08-26 | Open-market sale | Common Stock | 590 | $114 | $67.2K | 7,396 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-26 | Open-market sale (485 shares) |
| 2026-08-26 | Open-market sale (615 shares) |
| 2026-08-26 | Open-market sale (700 shares) |
| 2026-08-26 | Open-market sale (1,098 shares) |
| 2026-08-26 | Open-market sale (602 shares) |
| 2026-08-26 | Open-market sale (590 shares) |
Keywords
insider transaction, Form 4, MNPR, Monopar Therapeutics, bearish, Kim R Tsuchimoto
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.